Citable filing context
TMO's research view summarizes recent SEC filing context, starting with earnings from Jul 23, 2026.
| Filed | Item | Context |
|---|---|---|
| Jul 23, 2026 | earnings | Thermo Fisher Scientific reported Q2 2026 revenue of $11.99 billion, up 10%, and adjusted EPS of $6.03. |
| May 26, 2026 | other | Shareholders elected directors, did not approve executive compensation, and ratified auditor at the annual meeting. |
| Apr 23, 2026 | earnings | Thermo Fisher Scientific reported Q1 2026 revenue of $11.01 billion and adjusted EPS of $5.44. |
| Mar 24, 2026 | Guidance: adjusted_eps_contribution_from_acquisition | 0.45 to not reported |
| Mar 24, 2026 | Guidance: adjusted_operating_income_from_synergies | 175.00 to not reported |
| Mar 24, 2026 | Guidance: clario_business_growth_rate | not reported to not reported |
| Jul 31, 2026 | mda_quarterly | Thermo Fisher Scientific reported strong financial performance for the first half of 2026, with total revenues reaching $23.0 billion, an 8% increase over the prior-year period. Organic revenue growth was 3%, bolstered by a 10% revenue increase in the second quarter alone. Growth was primarily driven by the Laboratory Products and Biopharma Services segment, which benefited from the March 2026 acquisition of Clario Holdings, Inc., a provider of clinical trial data solutions. The Bioproduction business also saw significant demand from pharmaceutical and biotech customers. Operating margins expanded due to the company’s "Practical Process Improvement" (PPI) system, which drove productivity gains and cost efficiencies, partially offset by strategic investments and unfavorable business mix. The company continues to deploy capital through acquisitions and share repurchases, having bought back $4.0 billion of common stock in the first six months of 2026. While the company maintains a robust liquidity position, net interest expense rose due to increased debt levels used to fund capital deployment and the Clario acquisition. Management expects full-year 2026 capital expenditures to range between $1.9 billion and $2.1 billion, with a focus on capacity and capability investments to support long-term growth across its life sciences, analytical, and diagnostic markets. |
| May 1, 2026 | mda_quarterly | Thermo Fisher Scientific actively managed its capital structure and executive incentives during the first quarter of 2026. The company repurchased 4,869,851 shares of common stock in January at an average price of $616.04, totaling approximately $3 billion. This activity reduced the remaining authorization under its $5 billion share repurchase program, approved in November 2025, to $2 billion as of March 28, 2026. No further repurchases occurred in February or March. Financially, a key development was the extension of a credit agreement on February 4, 2026, which pushed the maturity date for participating lenders from January 7, 2027, to January 7, 2028, providing greater flexibility in debt management. Furthermore, new Restricted Stock Unit and Performance Restricted Stock Unit agreements were implemented for executive officers, including CEO Marc N. Casper, effective February 25, 2026. These awards incorporate both time-based and performance-based vesting criteria, with specific clauses addressing change in control, retirement, and various employment termination events, along with robust clawback provisions. No directors or executive officers adopted, modified, or terminated Rule 10b5-1 trading arrangements during the quarter. |
Source: SEC EDGAR filing text and events; period Jul 23, 2026; filed Jul 23, 2026.
TMO company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.